JAMA Network Open | 2021
Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China
Abstract
Key Points Question What is the prevalence of dyslipidemia in Chinese adults and what are the treatment and control rates of elevated low-density lipoprotein cholesterol in both primary and secondary prevention populations? Findings In this cross-sectional study of 2\u2009314\u2009538 community residents, 33.8% had dyslipidemia, 3.2% had established atherosclerotic cardiovascular disease (ASCVD), and 10.2% had high risk of ASCVD; 26.6% of those with ASCVD and 42.9% of those at high risk of ASCVD achieved low-density lipoprotein cholesterol control targets. Statins were available in 49.7% of the primary care institutions surveyed, with the lowest availability in rural village clinics. Meaning These findings suggest that dyslipidemia has become a major public health problem in China and is often inadequately treated and uncontrolled.